ReShape Lifesciences (Formally known as EnteroMedics)

280 articles with ReShape Lifesciences (Formally known as EnteroMedics)

• ReShape Lifesciences to Webcast Live at Life Sciences Investor Forum on December 16th

  12/9/2021

  ReShape Lifesciences Inc. today announced that Bart Bandy, Chief Executive Officer and President and Tom Stankovich, Chief Financial Officer of ReShape Lifesciences, will present a company overview live at VirtualInvestorConferences.com, at 2:00 pm ET on December 16th.     

• ReShape Reports Second Quarter 2021 Financial Results and Provides Business Update

  8/16/2021

  ReShape Lifesciences Inc., a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, reported its financial and operational results for the three months ended June 30, 2021.

• ReShape Lifesciences Completes $46 Million Capital Raise With Key Institutional Shareholders

  6/30/2021

  ReShape Lifesciences Inc., a global physician-led weight-loss and metabolic health solutions company, provided additional information about its previously announced warrant exercise agreement with existing accredited investors for approximately $46 million in gross proceeds.

• ReShape Lifesciences Closes First Day of Trading on the NASDAQ Capital Market

  6/17/2021

  ReShape Lifesciences Inc., a global weight-loss solutions leader, announced that its common stock effectively traded at a first day volume of over 3.5 million shares on The Nasdaq Capital Market under the ticker symbol "RSLS", following the previously announced completion of its merger with Obalon Therapeutics, Inc.

• ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Announce Anticipated Closing of Merger

  6/15/2021

  ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. announced the anticipated closing of their previously announced merger to be effective after the close of the market, June 15, 2021.

• ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Update on Status of Pending Merger

  6/8/2021

  ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. announced that the parties anticipate the closing of their previously announced merger to occur promptly after approval of their pending Nasdaq listing application.

• Obalon Therapeutics Continues to Urge Stockholders to Vote FOR All Proposals Related to Merger with ReShape Lifesciences

  5/21/2021

  Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled intragastric balloon system for the treatment of obesity, is taking this opportunity to remind its stockholders to vote on all the proposals related to the proposed merger with ReShape Lifesciences Inc. in advance of the upcoming reconvened special meeting of Obalon stockholders

• ReShape Lifesciences Announces First Quarter 2021 Financial and Operational Results

  5/17/2021

  ReShape Lifesciences Inc., a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, reported its financial and operational results for the three months ended March 31, 2021.

• ReShape Lifesciences Announces Fourth Quarter and Full Year 2020 Financial Results

  3/10/2021

  ReShape Lifesciences Inc., a global weight-loss solutions leader, reported financial and operational results for the fourth quarter and full year ended December 31, 2020.

• Reshape Lifesciences to Report Fourth Quarter and Full Year 2020 Financial and Operational Results on Wednesday, March 10, 2021

  3/8/2021

  Webinar to discuss results on March 10, 2021 at 4:30 p.m. E.T

• ReShape Lifesciences Announces Third Quarter 2020 Financial and Operational Results

  11/12/2020

  ReShape Lifesciences Inc., a global weight-loss solutions leader, reported financial and operational results for the three months ended September 30, 2020.

• ReShape Lifesciences to Report Third Quarter 2020 Financial and Operational Results on Thursday, November 12, 2020

  11/10/2020

  ReShape Lifesciences Inc., a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced that it will report its third quarter 2020 financial and operational results on Thursday, November 12, 2020 after the close of the U.S. financial markets.

• ReShape Lifesciences™ Announces Positive Preclinical Results for Its Investigational Diabetes Bloc-Stim Neuromodulation Device

  9/10/2020

  ReShape Lifesciences Inc., (OTCQB: RSLS) a global weight-loss solutions leader, today announced preclinical research demonstrating the Company's investigational Diabetes Bloc-Stim Neuromodulation™ (DBS

• ReShape Lifesciences Announces Second Quarter 2020 Financial and Operational Results

  8/13/2020

  ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, today reported financial and operational results for the three months ended June 30, 2020.

• ReShape Lifesciences to Report Second Quarter 2020 Financial and Operational Results on Thursday, August 13, 2020

  8/11/2020

  ReShape Lifesciences Inc., a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced that it will report its second quarter 2020 financial and operational results on Thursday, August 13, 2020 after the close of the U.S. financial markets.

• ReShape Lifesciences Recognizes National Parents' Day Offering New Resources for Women Considering Weight-Loss and Parenthood

  7/21/2020

  ReShape Lifesciences Inc., (OTCQB:RSLS) announced today that in recognition of National Parents' Day, it is providing updated information resources for women considering pregnancy that want to safely lose excess weight and experience the joy of parenthood.

• ReShape Lifesciences and inHealth Lifestyle Therapeutics Launch ReShapeCare(TM) Virtual Health Coaching for Patients with Obesity

  6/22/2020

  ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally-invasive medical devices to treat obesity and metabolic diseases, today announced a partnership with inHealth Lifestyle Therapeutics (formerly inHealth Medical Services), a Lifestyle Therapeutics company, to launch the ReShapeCare™ virtual health coaching program this month.

• 

  Year-End Research Advances Approaches, Both Genetic and Device-Oriented, to Treat Obesity

  12/27/2018

  Researchers at the University of Wisconsin-Madison have developed a battery-free, easily implantable device, about a third the size of a penny, that helped laboratory rats lose weight.

• Apollo Endosurgery, Inc. Announces the Sale of Its Surgical Product Line

  12/18/2018

  Apollo Endosurgery, Inc., today announced the sale of its Surgical product line, which consists of the Lap-Band® adjustable gastric banding system and other accessories used in laparoscopic bariatric surgery, to ReShape Lifesciences Inc.

• ReShape Lifesciences Announces European Trial to Support CE-Mark of ReShape Vest

  7/31/2018

  ReShape Lifesciences Inc. announced the Company has commenced site initiation training for the first clinical trial site that will participate in the multi-center trial of the ReShape VestTM to support CE Mark approval.